A professional view of how neurology HCPs approach pregnancy planning, antiseizure medication selection, fetal safety, serum-level monitoring, seizure recurrence, and postpartum dose management.
Audience: Neurology / Epilepsy HCPs
Countries: 6
Completion Rate: 61.6%
SGID: 9010428
-Hero findings
– Quick Read — Key Findings
For neurologists, reproductive planning can change medication strategy even when seizure control is otherwise stable.
Pregnancy planning is the reproductive presentation most often changing epilepsy management, at 56.3%, ahead of breakthrough seizures (18.8%), catamenial exacerbation (16.3%) and contraception planning (8.8%). That matters because preconception epilepsy care is not simply a medication-safety conversation but a timing problem: the window to review teratogenic risk, seizure history, contraception, folic acid and baseline drug levels is greatest before pregnancy starts.
Respondents are most likely to review antiseizure medication when reproductive intent becomes explicit.
Planned pregnancy is the strongest prompt to review the ASM regimen, selected by 73.4%, ahead of breakthrough seizures (38.0%), contraceptive interactions (34.2%) and ASM adverse effects (29.1%); because respondents could pick up to two, these are overlapping triggers. That places preconception review at the center of reproductive epilepsy care, echoing AAN/AES/SMFM guidance on choosing medications and doses that optimize seizure control and fetal outcomes at the earliest opportunity before pregnancy.
The respondents place medication-related fetal safety at the center of preconception selection.
Valproate teratogenicity and fetal neurodevelopmental risk are each selected by 40.5% as the factor that most influences preconception ASM choice, with enzyme-inducing interactions at 10.1% and seizure-control efficacy at 8.9% in this forced-choice question. This does not mean seizure control becomes secondary in real care: guidance stresses both goals, minimizing convulsive seizures while reducing fetal exposure to higher-risk drugs where feasible, so the tension is not safety versus efficacy but how to protect both.
The biggest complication identified in the survey is not a laboratory value or a side effect. It is the absence of time to plan.
Unplanned pregnancy is the factor that most commonly complicates reproductive epilepsy management, selected by 65.4%, ahead of ASM adherence (17.9%), contraceptive interactions (11.5%) and inadequate folic acid use (5.1%). When pregnancy begins unexpectedly, clinicians may have to reassess medication risk after fetal exposure has already occurred while protecting seizure control, and the AAN/AES/SMFM guideline cautions against destabilizing an effective regimen once pregnancy has begun, especially when it controls convulsive seizures.
Preconception management appears individualized rather than driven by one universal medication move.
Switching to a lower-risk ASM is the most selected strategy at 39.0%, but many clinicians reassess the regimen (24.7%), continue effective monotherapy (23.4%) or optimize dose (13.0%) rather than switch automatically. That reflects a familiar reality: changing medication can reduce fetal-exposure risk but can also threaten seizure stability, so a lower-risk option only helps if it suits the epilepsy syndrome and maintains control.
The medication that worked before pregnancy may not produce the same exposure throughout pregnancy.
Falling serum ASM levels are the pregnancy change that most alters management, selected by 46.8%, ahead of breakthrough generalized seizures (35.1%), non-adherence (11.7%) and hyperemesis affecting absorption (6.5%). NICE recommends considering baseline preconception concentrations for selected ASMs and monitoring levels during pregnancy when appropriate, and the finding shows why: drug concentration, seizure recurrence, adherence and fetal safety become connected rather than separate issues.
The survey tells a consistent story: reproductive epilepsy management works best when pregnancy is anticipated early enough to review the medication regimen, understand fetal risk, establish a monitoring plan, and protect seizure control before physiology and time pressure begin changing the equation.
The strongest complication is unplanned pregnancy, while planned pregnancy is the strongest trigger for review, making preconception care the hinge point of the entire pathway.
Pregnancy then adds a second layer as drug concentrations may fall and seizure recurrence becomes a major signal, and postpartum care requires another deliberate transition as doses and serum levels return toward the pre-pregnancy state.
What respondents want most is not more monitoring technology but safer pregnancy-compatible antiseizure medication, so the core clinical need is unchanged: preserve seizure control while reducing avoidable reproductive risk across the full reproductive journey.
You have read the summary
Explore the complete findings in the full report, or join MDForLives to contribute your perspectives to future healthcare research.
Direct answers to common professional questions about antiseizure medication selection, pregnancy monitoring, fetal safety, folic acid, and postpartum dose management.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
